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Forced degradation study on doxorubicin (DOX) was carried out under hydrolytic condition in acidic,
alkaline and neutral media at varied temperatures, as well as under peroxide, thermal and photolytic
conditions in accordance with International Conference on Harmonization (ICH) guidelines Q1(R2). It
was found extremely unstable to alkaline hydrolysis even at room temperature, unstable to acid hy-
drolysis at 80 °C, and to oxidation at room temperature. It degraded to four products (O-I–O-IV) in
oxidative condition, and to single product (A-I) in acid hydrolytic condition. These products were re-
solved on a C8 (150 mm4.6 mm, 5 mm) column with isocratic elution using mobile phase consisting of
HCOONH4 (10 mM, pH 2.5), acetonitrile and methanol (65:15:20, v/v/v). Liquid chromatography–pho-
todiode array (LC–PDA) technique was used to ascertain the purity of the products noted in LC–UV
chromatogram. For their characterization, a six stage mass fragmentation (MS6) pattern of DOX
was outlined through mass spectral studies in positive mode of electrospray ionization (þESI) as well
as through accurate mass spectral data of DOX and the products generated through liquid chromato-
graphy–time of ﬂight mass spectrometry (LC–MS–TOF) on degraded drug solutions. Based on it, O-I–O-IV
were characterized as 3-hydroxy-9-desacetyldoxorubicin-9-hydroperoxide, 1-hydroxy-9-desacetyldox-
orubicin-9-hydroperoxide, 9-desacetyldoxorubicin-9-hydroperoxide and 9-desacetyldoxorubicin, re-
spectively, whereas A-I was characterized as deglucosaminyl doxorubicin. While A-I was found to be a
pharmacopoeial impurity, all oxidative products were found to be new degradation impurities. The
mechanisms and pathways of degradation of doxorubicin were outlined and discussed.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Drug regulatory agencies such as United States Food and Drug
Administration (USFDA) and ICH have laid down very stringent
guidelines for the control of impurities in drug substances and
products [1–6]. ICH Q3A(R2) and Q3B(R2) guidelines speciﬁcally
require the identiﬁcation of impurities (process or degradation
related) in any drug substance and product [3,4]. Identiﬁcation of
degradation related impurities (degradation products) remains a
major challenge during product development. These arise due to
chemical susceptibility of a drug molecule to varied chemical en-
vironments during product development, transportation and shelf
life. Moreover, these are formed generally in minute amounts,
which may not be sufﬁcient to facilitate their characterization.
Hence, ICH Q1A(R2) guidelines recommend forced degradation
study (stress testing) on drug substance under different chemicalon and hosting by Elsevier B.V. All
University.environments to facilitate isolation and/or characterization of all
possible/major degradation products of the drug [2].
Anthracyclines constitute an important class of anti-tumor
chemotherapeutic drugs with a broad spectrum of anticancer ac-
tivity. DOX (also known as adriamycin) is a naturally anthracycline
derivative and is a hydroxylated analog of daunorubicin (Fig. 1). It
is particularly used for the treatment of disseminated neoplastic
conditions such as acute lymphoblastic leukemia, acute myelo-
blastic leukemia, Wilm's tumor, neublastoma, soft tissue and bone
sarcomas, breast carcinoma, ovarian carcinoma, transitional cell
bladder carcinoma, thyroid carcinoma, Hodgkin's and non-Hodg-
kin's lymphomas, bronchogenic carcinoma and gastric carcinoma
[7,8]. DOX is an important component of multi-chemotherapeutic
drug regimen, and is usually given combined with cyclopho-
sphamide, vincristine, bleomycin or prednisone. It is ofﬁcial in
British Pharmacopoeia, United States Pharmacopoeia, Indian
pharmacopoeia and Martindale [9–12]. The monograph about DOX
in British Pharmacopoeia lists four impurities (Imp A–Imp D) [9]
(Fig. 1). Some studies have reported on degradation and stability of
DOX under varied conditions such as aqueous, photolytic and biolo-
gical environments [13–20]. Of these, only Cielecka-Piontek et al. [13]rights reserved. This is an open access article under the CC BY-NC-ND license
Fig. 1. Structure of doxorubicin (DOX) and its known impurities.
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ubicin in solid state degrade to apolar degradation products that
behave like 7-deoxyaglycons. None of other studies has characterized
the degradation products formed under different conditions. Herein,
we report (i) a comprehensive forced degradation study on DOX
under hydrolytic, photolytic, oxidative and thermal degradation
conditions as prescribed in ICH Q1(R2) guidelines; (ii) structural
characterization of degradation products throughmass fragmentation
and accurate mass spectral analyses; and (iii) most plausible me-
chanisms of DOX degradation.2. Experimental
2.1. Drug and chemicals
Doxorubicin hydrochloride (DOX) was generously provided by
Strides Arcolabs Pvt. Ltd. (Bangalore, India) as a gift sample. All
analytical grade chemicals (sodium hydroxide, hydrochloric acid,
hydrogen peroxide (30%) and ammonium formate) were supplied by
Loba Chemical Pvt. Ltd. (Mumbai, India). The high performance liquid
chromatography (HPLC) grade solvents and chemicals (methanol,
acetonitrile and formic acid) were procured from Merck Specialist
Pvt. Ltd. (Mumbai, India). HPLC grade water was obtained from Direct
Ultra water puriﬁcation system (Bio-Age Equipment and Services,
SAS Nagar, India) in the laboratory.2.2. Equipments
A high precision water bath and a hot air oven digitally con-
trolling temperature variation of 1 and 2 °C, respectively (Narang
Scientiﬁc Works, New Delhi, India) were employed for hydrolytic
and thermal degradation studies. Photostability chamber which is
equipped with digital controller capable of maintaining tempera-
ture and relative humidity (RH) within 72 °C and 75%, respec-
tively (KBF 240, WTB Binder, Tuttlingen, Germany) was used for
photodegradation studies. The light sources ﬁxed in the chamber
provided an illumination bank in compliance with ICH guideline
Q1B [21]. Liquid chromatography–ultraviolet (LC–UV) analyses of
the forced degradation samples were carried out on a a binary
HPLC system (515 pumps) equipped with a Rheodyne manual in-
jector and a 2487 dual wavelength detector controlled by Em-
power 2 software (Waters, Milford, MA, USA). An Agilent C8
(150 mm4.6 mm, 5 mm) column was used for chromatographic
separation of the drug and degradation products. Purity of peaks of
DOX and products in the degradation samples were ascertained by
LC–PDA analysis using a binary HPLC system consisting of a 2707
auto-injector and a 2998 PDA detector (Waters, Milford, MA, USA).
LTQ-XL ion trap quadrupole mass spectrometer (Thermo Scientiﬁc,
Germany) was used to record multi-stage mass spectral (MSn) data
of DOX in positive mode of electrospray ionization (þESI). For LC–
MS–TOF analyses of DOX and degradation products, an Agilent
1100 series LC system (Agilent Technologies Inc., CA, USA) con-
trolled by Hystar (Ver.3.1) software coupled with a microTOF-Q11
mass spectrometer (Bruker Daltonics GmbH, Germany) controlled
Fig. 2. Chromatogram of standard solution of DOX (A), and DOX solutions exposed to 0.1 M HCl at 80 °C (B), 30% H2O2 at room temperature (C), and 0.1 M NaOH at 80 °C (D).
Table 1
Clog P values and peak purity data of DOX and its degradation products.
Analyte Clog P Purity angle Purity threshold
DOX 0.4614 0.972 2.201
O-I 1.7432 0.629 2.107
O-II 1.0337 0.783 3.095
O-III 0.8857 0.861 2.981
O-IV 1.5753 0.648 1.732
A-I 0.0695 1.029 2.985
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entry of only 35% of the eluent was placed before the mass
detector in order to avoid signal saturation and detector
contamination.
2.3. Forced degradation
DOX was exposed to conditions of hydrolysis, oxidation, dry
heat and photolysis. Concentration of DOX in solution/suspension
for the study was 0.1% (m/v). Solutions/suspensions of DOX in
water, NaOH (0.1 M) and HCl (0.1 M) were exposed to 80 °C for a
period of 8 h for hydrolytic degradation. Suspension of DOX in
H2O2 (30%) was placed at 3075 °C in dark for 24 h for oxidative
degradation. DOX in solid state was sealed in amber color vials and
placed in hot air oven maintained at 50 °C for 30 days for thermal
degradation. For photolytic degradation, 2 mL of a solution of DOX
in acetonitrile was mixed with 3 mL of each stressor separately (i.e.
0.1 M HCl, 0.1 M NaOH and water) in transparent glass vials. These
vials as well as the solid drug spreading as a thin layer in a petri
dish were placed in the photostability chamber for 14 days to
expose the samples to about 200 W h/m2 of UV light and
1.2 million lx h of white light. Another similar set of solid drug and
drug solutions wrapped well in aluminum foil was also placed inthe photostability chamber for the same period of time and served
as dark control. Samples from each degradation condition were
stored at 4 °C till analysis.
2.4. LC–UV and LC–PDA analyses
For chromatographic analysis, the thermal and photodegraded
DOX in solid state was solubilized in methanol to produce solu-
tions of concentration 0.1% (m/v). Each of these solutions as well as
drug solutions/suspensions exposed to hydrolytic, oxidative and
photolytic degradation conditions was diluted (1 in 10) with mo-
bile phase. The drug suspension, wherever formed, was stirred
well and sonicated for 5 min to make a homogenous suspension,
whereas the acid and alkali degraded drug solutions were neu-
tralized before dilution. Each diluted sample was ﬁltered through a
nylon membrane (0.45 mm, 13 mm) before injected on the HPLC
system. Blank solution corresponding to each sample was also
processed similar to the sample and its LC–UV analysis precedes
that of the sample. Chromatographic separation of DOX and its
degradation products was achieved by running 20 μL of degraded
drug solution on a C8 column (150 mm4.6 mm, 5 mm, Agilent)
by isocratic elution with mobile phase composed of ammonium
formate (10 mM, pH 2.5), acetonitrile and methanol (65:15:20, v/v/v)
at a ﬂow rate of 1 mL/min at ambient temperature (2772 °C).
The eluent was detected at 234 nm. The purity of DOX and all its
degradation products peaks in LC–UV chromatograms were es-
tablished through LC–PDA analysis.
2.5. þESI-MSn and LC–MS–TOF studies
Six stage mass spectra of DOX in þESI mode were recorded
(þESI-MS6) using ionization potentials increasing from 18.0 V to
28.0 V, and rationally selecting the precursor ion for each stage.
Operating parameters of mass detector such as end plate offset
Fig. 3. Six stage mass fragmentation spectra of DOX. The precursor ion targeted to record each mass spectrum is marked by “*”.
Table 2
Precursor/parent ions and product ions in MS6 studies.
MSn stage Precursor ion (m/z) Product ions (m/z)
MS1 544 [MþHþ] 100%
MS2 544 526, 415, 397, 379, 361, 321
MS3a 526 508, 397, 379, 361, 321
MS3b 415 414, 397
MS4 397 379, 337
MS5 379 361, 321, 309
MS6 361 346, 333
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and dry temperature for recording MS6 spectra of DOX as well as
LC–MS–TOF spectra of DOX and degradation products were opti-
mized as 500 V, 4500 V, 400.0 vpp, 1.2 bar, 6.0 L/min and 200 °C,
respectively. The LC–MS–TOF analyses were carried out by using
ionization potentials of 10 and 15 V. All MS and TOF spectra were
recorded over a mass range of 50–1000. Masses of various ion
peaks in TOF spectra were recorded up to the fourth decimal
precision for accurate mass measurements.3. Results and discussion
3.1. Forced degradation behavior
DOX was detected as a sharp peak at 25.15 min wherein no
impurity was noted in LC–UV chromatogram of standard solution
(Fig. 2A). It degraded to a single product (A-I) under acid hydro-
lytic condition after 8 h (Fig. 2B), and four products (O-I–O-IV)
under oxidative condition over 24 h (Fig. 2C). LC–PDA studies on
acid hydrolyzed and oxidized drug solutions showed that purity
angles of the peaks of DOX, O-I, O-II, O-III and O-IV and A-I were
less than their purity threshold (Table 1), which indicated that all
peaks were pure and no other products co-eluted with any of
these peaks. Exposure of the drug to hydrolysis in water at 80 °C
for 8 h, and to thermal degradation condition for 30 days produced
no degradation products. In contrast, its exposure to 0.1 M NaOH
at 80 °C for 8 h caused its almost total degradation (Fig. 2D). Even
in mild alkaline medium (0.01 M NaOH) at 40 °C (Supplementary
Fig. S2A) as well as at room temperature within 30 min, the drug
degraded almost completely to several degradation products. In all
alkali degradation conditions, the products were eluted as
Fig. 4. Mass fragmentation pattern of DOX and its acid degradation product (A-I). The dotted arrows outline the fragmentation pathways of A-I.
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solved even after numerous modiﬁcations under chromatographic
conditions such as composition of mobile phase, pH of buffer and
stationary phase. Four LC–UV chromatograms showing the best,
but still unacceptable resolution are given in Supplementary Fig.S1. The degradation behavior of DOX under acidic and alkaline
hydrolytic, and oxidative conditions was in consonant with the
ﬁndings by other laboratories [13–18]. Comparison of the LC–UV
chromatograms of the drug exposed to photolytic conditions
(Supplementary Fig. S2B and D) with those of the drug stored in
Fig. 5. LC–MS–TOF spectra of DOX and its degradation products (* indicates the parent ion).
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respectively revealed that no peak was formed due to photo-
degradation. Also, no additional photodegradation product was
formed when solid drug was exposed to the photolytic conditions
(Supplementary Fig. S2F). It indicates that degradation pattern of
DOX under photolytic conditions in acidic and alkaline media is
similar to that under hydrolytic condition, and hence the drug is
suggested to be photostable.
However, these results of photostability of DOX are found
conﬂicting, at the outset, with those in available reports on pho-
todegradation of DOX. Wood et al. [15,16] have conducted a pho-
todegradation study on DOX at different pH and in different con-
tainers. They found that (i) DOX degraded due to cleavage of gly-
cosidic linkage in different media under photolytic conditions; (ii)
both the glass and polyethylene container adsorb DOX; and (iii)
the rate of drug degradation was inversely proportional to its
concentration (i.e. 10% degradation in 100 mg/mL solution of DOX
and 460% degradation in 10 mg/mL solution after 168 h exposure
to visible light). Nonetheless, the ﬁrst two interpretations may not
be considered really true with reference to our explanations that
are as follows: Firstly, the glycosidic linkage is known to cleave
under mild acid hydrolytic as well as strong alkaline hydrolytic
conditions. However, there is no documented proof of its photo-
lytic cleavage. Therefore, DOX might have degraded due to hy-
drolysis but not photolysis. Secondly, the major decrease in con-
tent of DOX in the degraded solution may also be, most likely, due
to adsorption of DOX on the sample containers in addition to the
actual degradation. The third ﬁnding actually acts as a support to
photostability of DOX in the present study because herein we have
subjected DOX to different degradation conditions using a solution
of concentration 1000 mg/mL, which, according to Wood et al.
[15,16] degrades at the least rate. In another study, DOX was found
to degrade to 3-methoxysalicyclic acid and an unstabledihydroquinone after exposure to laser beam (λ 483 nm) for 48 h.
These two products react with oxygen available in reaction mix-
ture and form DOX and H2O2. Hence, there was no net loss/de-
gradation of DOX [15]. Other photodegradation studies have re-
vealed that DOX degrades after exposure to long UV light in the
presence of photosensitizers such as riboﬂavin. This riboﬂavin
mediated photooxidation of DOX is further increased in the pre-
sence of histidine and urocanic acid [17–19]. The results of these
literature reports suggest that the photodegradation of DOX is
either reversible or is mediated by a photosensitizer. In th present
study, the degradation of DOX was carried out using a drug con-
centration of 1000 mg/mL without any photosensitizer. Hence, the
drug does not degrade, and is termed as photostable under the
tested conditions. However, in general, as light exposure tends to
accelerate most chemical reactions, the drug may be re-
commended to be stored in containers affording protection from
light. In addition, the drug is found stable at neutral pH, but its
stability decreases signiﬁcantly with increasing or decreasing the
pH beyond 7.
3.2. Mass fragmentation pattern of DOX
Sleno et al. [22] have reported the mass fragmentation pattern
of DOX on the basis of MS3 spectra. In the present study, six stage
mass fragmentation spectra (MS6) of DOX were recorded (Fig. 3)
for assisting the characterization of degradation products. The
drug was detected at m/z 544 as parent ion (M1) in MS1 (Fig. 3A)
corresponding to its molecular mass of 543 Da. The various pro-
duct ions formed from M1 and different precursor ions in all six
stages are summarized in Table 2. Based on the comparison of
product ions formed from different precursor ions in all mass
spectra, a systematic mass fragmentation pattern of DOX was
outlined (Fig. 4). The product ions formed directly from the
Table 3
Molecular formulae corresponding to the measured mass of various peaks in MS–TOF spectra of DOX and products O-IV, O-III and A-I.
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and subsequently, M1 fragmented directly to product ions of m/z
526, 415 and 397 (Fig. 3B) by the loss of water and amino sugar
moiety as speciﬁed in Fig. 4. The heaviest fragment m/z 526 (M2a)
was used as precursor ion to record MS3a spectrum wherein it
fragmented to product ions ofm/z 508 by the loss of water andm/z
397 by the loss of amino sugar moiety (Fig. 3C). The fragment of
m/z 415 (M2b) fragmented to m/z 414 and 397 in MS3b through the
loss of a hydrogen radical and amino sugar moiety, respectively
(Fig. 3D). Incidentally, product ion of m/z 397 was formed in MS2,
MS3a as well as MS3b. Hence, it was taken as precursor ion to re-
cord subsequent mass spectra. Fragmentation of m/z 397 (M3)
produced product ions of m/z 379 (M4) and 337 in MS4 spectrum
due to the loss of water molecule and a C2H4O2 respectively from
side chain of ring A (Fig. 3E). The heaviest fragment of m/z
379 (M4) in MS4 spectrum was further fragmented to product ions
ofm/z 361 (M5), 321 and 309 (Fig. 3F). Finally, M5 was employed as
precursor ion to generate MS6 spectrum wherein it fragmented to
product ions of m/z 333 by the loss of CO moiety [22] and m/z 346
by the loss of a methyl radical (Fig. 3G). In addition to MS6 study,
DOX was also analyzed through LC–MS–TOF to generate accurate
mass spectral data. The TOF spectrum of DOX (Fig. 5A) showed
parent ion at m/z 544.1799. The major fragments were noted at m/
z 526.1619, 415.1024, 397.0902. 379.0807, 361.0742 and 321.0751.
These masses were found to be very close to the theoretical ac-
curate masses and the structures of product ion of m/z 526, 415,
397, 379, 361 and 321 (Table 3) formed during MS6 study which
supported the proposed structural assignment to these ions.3.3. LC–MS–TOF studies for characterization of degradation products
Structures of the degradation products were characterized with
the help of MS6 fragmentation pattern of DOX, comparative ac-
curate mass spectral data of the drug and products generated
through LC–MS–TOF analysis of degraded drug solutions, and
Elemental Composition Calculator Software that provided the
most probable molecular formula corresponding to ion peaks in
the mass spectra. The four oxidative products (O-I–O-IV) and the
single acid hydrolyzed product (A-I) detected in LC–UV chroma-
togram were detected in total ion chromatogram (TIC). The LC–
MS–TOF spectra of DOX and each product are given in Fig. 5 and
their accurate mass spectral data are summarized in Table 3 and 4.
3.3.1. Product O-IV
The heaviest peak in MS–TOF spectrum of O-IV was noted atm/
z 484.1593 (Fig. 5B) which was assigned as its parent ion (MIV)
peak. An even molecular mass of MIV suggested an odd number
nitrogen atom [23]. Hence, the single nitrogen atom in amino
sugar component of DOX was intact in O-IV. The mass difference of
60.0226 Da between M1 and MIV was found to correspond to
molecular formula C2H4O2 (60.0231 Da) [24]. The possible mole-
cular structures corresponding to C2H4O2 include acetic acid,
2-hydroxyacetaldehyde (OHCH2CHO) and 1,2-ethylenediol. Out of
these, 2-hydroxyacetaldehyde was possible to form from hydro-
xylacetyl side chain on ring D of DOX. Hence, O-IV was proposed
to form by the loss of COCH2OH group from DOX that was
possible through Baeyer Villiger oxidation in the presence
of H2O2. Based on this proposition, O-IV was suggested to be
Table 4
Molecular formulae corresponding to the measured mass of various peaks in MS–QTOF spectra of products O-I and O-II.
Fig. 6. Proposed mass fragmentation pattern of oxidative products (O-I–O-IV). The fragments superscripted with “a” belong to O-I while those with “b” belong to O-II.
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enol tautomerism. This proposition was supported by a similar
kind of product under oxidative conditions reported to form from
idarubicin [25]. The TOF spectrum of O-IV showed product ions at
m/z 355.0797, 337.0721 and 309.0737. The fragment of m/z
355.0797 was 129.0796 Da less than MIV and was proposed to
form by the loss of amino sugar moiety from MIV similarly as M2b
forming from M1 and M2a, respectively. The m/z values 337.0721and 309.0737 matched very closely with accurate theoretical mass
of structures assigned to fragments m/z 337 and 309, respectively,
in MS4 and MS5 spectra of DOX. Based on this comparative mass
spectral data, the suggested structure of O-IV was proposed to
undergo fragmentation as shown in Fig. 6. The fragment of m/z
309.0737 was possible to form from m/z 337.0721 by the loss of CO
group (27.9984 Da) similar to mass fragmentation of phenols or
alcohols reported in standard literature [24].
D. Kaushik, G. Bansal / Journal of Pharmaceutical Analysis 5 (2015) 285–295 2933.3.2. Product O-III
It was detected as the heaviest and major peak at m/z 518.1647
(Fig. 5C) that was assigned as its parent ion (MIII) peak. An even
molecular mass of MIII suggested an odd number of nitrogen
atoms [23]. Hence, the single nitrogen atom present in amino
sugar component of DOX was suggested to be intact in O-III, si-
milarly as in O-IV. The MS–TOF spectrum also showed fragment
ion of m/z 500.1539, 484.1603, 371.0745, 355.0802, 337.0729,
325.0378 and 309.0745. Of these, the fragments of m/z 484.1603,
355.0802, 337.0729 and 309.0745 were also noted in TOF spectrum
of O-IV. It indicated that O-III may be a derivative of O-IV itself. MIII
was 34.0044 Da heavier than m/z 484.1603, and this mass differ-
ence was found to correspond to an H2O2 molecule (34.0055 Da)
[24]. Based on these results, it was suggested that O-III might be
formed by the addition of H2O2 across the ketone group generated
on ring D in keto form of O-IV. This contention was supported by
an earlier study, in which a similar hydroperoxide degradation
product was proposed to form from idarubicin [25]. Hence, O-III
was proposed to be 9-desacetyldoxorubicin-9-hydroperoxide,
which underwent mass fragmentation (Fig. 6) in consonant with
its MS–TOF spectrum. The fragment of m/z 484.1603 was possible
to form by the loss of H2O2 from MIII, whereas the product ions of
m/z 355.0802, 337.0729 and 309.0745 were proposed to formFig. 7. Mechanism of dsimilarly as from MIV. The product ions of m/z 500.1539 and
371.0745 were possible to form by the loss of H2O molecule fol-
lowed by the loss of X-H. The fragment of m/z 325.0387 was
proposed to form from m/z 371.0745 through one or two steps.
3.3.3. Products O-II and O-I
The LC–MS–TOF spectra of O-II and O-I showed major and
heaviest peaks at m/z 534.1595 and 534.1601, hence they were
assigned as parent ions (MII and MI, respectively) (Fig. 5D and E).
An even mass of MI and MII suggested an odd number of nitrogen
atoms in the products [23], which indicated the single nitrogen
atom in the amino sugar component in DOX to be intact in both
O-I and O-II. The very similar values of MI and MII (Tolerance of 0.7%
as per Elemental Composition Calculator Software) indicated that
both O-I and O-II have the same chemical formula. However, O-I
and O-II eluted at different retention times i.e. 6.9 min and 7.8 min,
respectively (Fig. 2), which suggested these products have differ-
ent structures. The TOF spectra of both products displayed the
same fragment ions (Fig. 5D and E). This comparative information
on chromatographic and mass spectral data of O-I and O-II sug-
gested that though they have similar chemical formula, they have
different structures, which may be isomers. The TOF spectrum of
O-II showed fragment ions of m/z 500.1532, 387.0728, 371.0736,egradation of DOX.
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500.1532) was 34.0063 Da less than that of MII, and this mass dif-
ference was found to correspond to an H2O2 molecule (34.0055 Da).
The same fragment was also noted as the heaviest fragment in TOF
spectrum of O-III, wherein it was proposed to form by the loss of a
water molecule (Fig. 6). Moreover, MIII was also found to fragment to
m/z 484.1603 (MIV) by the loss of an H2O2 molecule (Fig. 6). These
comparisons in mass spectral data indicated that hydroxyhyroper-
oxide moiety is present in MII, similarly as in MIII, which implied that
O-II is a derivative of O-III itself. Further, the mass difference of
15.9958 Da between MIII and MII was found to correspond to an
oxygen atom (15.9949 Da). It suggested that O-II might form by the
addition of an oxygen atom in MIII under the oxidative condition,
which was possible through peroxide catalyzed oxidation of ring A
leading to the formation of a hydroxylated (phenol) derivative. Fur-
ther, this hydroxylation in ring A could occur at position ortho or para
with respect to methoxy group (activating group). A logical co-rela-
tion among chromatographic elution data and comparative mass
spectral data of O-I and O-II, and possibility of hydroxylation in ring A
of DOX suggested that O-I and O-II might be positional isomers (ortho
and para) of the hydroxylated derivative of O-III. As O-II eluted after
O-I (Fig. 2), O-I might be more polar than O-II. This co-relation be-
tween polarity and elution order was supported by the observation
that elution order of O-III, O-IV and DOX was in concordance with
their lipophilicity, determined as Clog P by ChemBioDraw Ultra 12.0
software (Table 1). The possible ortho hydroxyl derivative of O-III was
predicted to be more polar than the para isomer (Table 1). Hence, O-I
was proposed to be an ortho isomer (o-anisole derivative) whereas
O-II to be the para isomer (p-anisol derivative), which underwent
mass fragmentation in agreement with their mass spectral data
(Fig. 6). Hence, O-I and O-II were suggested to be 3-hydroxy-9-de-
sacetyldoxorubicin-9-hydroperoxide and 1-hydroxy-9-desacetyldox-
orubicin-9-hydroperoxide, respectively.
3.3.4. Product A-I
It was detected as the heaviest ion peak at m/z 415.1024 (Fig. 5F),
which was assigned as its parent ion (MA) peak. An odd molecular
mass of MA indicated an even number nitrogen or no nitrogen atom
[23], which suggested that amino sugar moiety might be absent in A-I.
MA was also noted as a product ion in MS2 spectrum of DOX, wherein
it was proposed to form by the loss of amino sugar moiety (X-H) from
the parent ion of DOX. Based on this, A-I was proposed to be deglu-
cosaminyl doxorubicin formed by the loss of the glucosamine moiety
due to cleavage of glycosidic linkage between the tetracycline ring and
the glucosamine moiety. Mass fragmentation of the proposed A-I to
product ions ofm/z 397.0914, 379.0824, 361.0781 and 321.0745 (Fig. 4)
was in agreement with its TOF spectrum.
3.4. Drug degradation mechanisms
Degradation of DOX to deglucosaminyl doxorubicin (A-I) under
acid hydrolytic condition was possible through well known acid
catalyzed cleavage of glycosidic linkage (Fig. 7) similar as the
reports on the degradation of other similar drug molecules such as
idarubicin, doxorubicin, 4′-deoxydoxorubicin, 4′-O-methyl doxor-
ubicin, 4′-epidoxorubicin, doxorubininol, daunorubicin and carmi-
nomycin under acidic conditions [14,25]. Degradation of DOX to
O-IV (9-desacetyldoxorubicin) and then to O-III (9-desacetyldoxor-
ubicin-9-hydroperoxide) was possible through Baeyer Villiger
oxidative deacetylation following the addition of H2O2 (Fig. 7),
similar to the oxidative degradation of idarubicin [25]. The pro-
ducts O-I (3-hydroxy-9-desacetyldoxorubicin-9-hydroperoxide) and
O-II (1-hydroxy-9-desacetyldoxorubicin-9-hydroperoxide) were pro-
posed to form by peroxide assisted hydroxylation in ring A of doxor-
ubicin. This proposition was supported by a report that disclosed and
discussed the formation of alkoxy and aryloxy substituted phenolsfrom the corresponding alkoxy and aryloxy benzene [26]. However, a
comparison of the results of the present study with degradation be-
havior of idarubicin reported earlier by our laboratory [25] revealed
that such hydroxylated products did not form from idarubicin. This
difference in degradation behaviors of doxorubicin and idarubicin was
attributed to the methoxy group in ring A in doxorubicin, which is a
moderate activating group and directs substitution at ortho and para
position [27].4. Conclusion
DOX was subjected to forced degradation under the conditions of
hydrolysis (water, acid and alkali), peroxide oxidation, dry heat and
photolysis as recommended in ICH guidelines Q1(R2). DOX degraded
to several degradation products in alkaline medium even at room
temperature that could not be resolved. Four degradation products
(O-I–O-IV) were formed in oxidative conditions, and a single product
(A-I) was formed in acid hydrolytic condition. They were resolved by
a single isocratic LC–UV method and characterized by MS6 and LC–
MS–TOF studies as 3-hydroxy-9-desacetyldoxorubicin-9-hydroper-
oxide (O-I), 1-hydroxy-9-desacetyldoxorubicin-9-hydroperoxide (O-
II), 9-desacetyldoxorubicin-9-hydroperoxide (O-III), 9-desacetyldox-
orubicin (O-IV), and deglucosaminyl doxorubicin (A-I). While O-I–O-
IV were found to be new degradation impurities, A-I was found to be
a pharmacopoeial impurity of DOX. The drug remained stable to
hydrolytic degradation in neutral medium, thermal degradation and
photolytic degradation.Acknowledgments
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